News

The trial aims to evaluate the safety, tolerability and pharmacokinetics of PRC-4016 in healthy volunteers. Pronova CEO Morten Jurs said they believe PRC-4016 has an optimal profile to

The patent includes composition of the Vaxfectin adjuvant, composition of Vaxfectin-formulated vaccines, and methods for their use. Vical president and CEO Vijay Samant said Vaxfectin was discovered through

Lubrizol is a producer of ingredients and additives for personal care products and pharmaceuticals; specialty materials, as well as plastics technology and performance coatings in the form of

The randomized, placebo-controlled, double-blind study is designed to prove the concept of the use of EMA401 in PHN patients and to demonstrate its pharmacokinetic profile, tolerability, and safety.

Following the merger, the businesses were brought together under a newly-formed company, Alkermes plc, to be based in Ireland. As per the terms of the deal, Elan has

Under the agreement, both the parties have invested for combining Selcia’s medicinal and analytical chemistry, with NeuroVive’s research and development programs in mitochondrial medicine. NeuroVive CEO Mikael Bronnegard

Earlier, the company has received a warning letter from the agency on 25 August 2010 for violating good manufacturing practice regulations. The issuance of the letter follows FDA

The new deal covers several major European countries, such as Germany, France, the UK, Spain, Austria, the Netherlands and Belgium. Under the deal, Meda is responsible to pay

The funding will also support the company in conducting a first-in-man dose ranging study to evaluate the anthrax vaccine. Vaxin president and CEO Bill Enright said this is